KDM1A inhibitors for the treatment of disease
US11932629B2 · kind B2 · utility
0Cited by
9References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2022 |
| Grant date | Mar 19, 2024 |
| Priority date | — |
| Expiry date | Dec 15, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.